<DOC>
	<DOCNO>NCT00793221</DOCNO>
	<brief_summary>Chronic total coronary occlusion ( CTO ) especially high risk angiographic restenosis , need new revascularization procedure . Drug-eluting coronary stent ( DES ) demonstrate significantly reduce risk restenosis new revascularization procedure comparison bare-metal stent . Most data efficacy DES come sirolimus-eluting coronary stent Cypher ( Cordis corp. ) , paclitaxel-eluting coronary stent Taxus ( Boston Sci . ) , Cypher stent DES randomly test CTO . Among second-generation DES , everolimus-eluting stent ( EES ) show excellent angiographic clinical result , DES study unfavourable scenario ( CTO ) . The aim CIBELES trial demonstrate hypothesis EES equally effective comparison sirolimus-eluting stent treatment CTO , term angiographic efficacy consider in-stent late lumen loss .</brief_summary>
	<brief_title>Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients â‰¥ 18 yearold . A total occlusion ( TIMI 01 ) estimate time occlusion &gt; 2 week . Symptomatic silent ischaemia , viable myocardium . The occlusion suitable percutaneous coronary intervention . The guidewire cross occlusion , occlusion dilate balloon device . Acute myocardial infarction myocardial area supply target vessel within 2 week inclusion study . The lesion cross guidewire balloon angioplasty . The vessel previously treat percutaneously . The lesion suitable 2.253.5 coronary stent implantation . The patient willing undergo angiographic followup . The patient contraindication prolong double ( aspirin plus clopidogrel ) antiplatelet therapy ( e.g . allergy aspirin , need chronic oral anticoagulation , schedule surgical intervention within 12 month . Pregnancy absence pregnancy test woman childbearing age . Chronic renal failure ( creatinine plasmatic value &gt; 3.0 mg/dl ) . Plasmatic platelet count &lt; 100.000 mm3 &gt; 700.000 mm3 . The patient severe noncardiac disease limit his/her life expectancy &lt; 1 year . The patient currently include randomize trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Coronary stent .</keyword>
	<keyword>Restenosis .</keyword>
	<keyword>Coronary artery disease .</keyword>
	<keyword>Chronic total occlusion .</keyword>
</DOC>